SCHEMBL184853

SCHEMBL184853

O=C(O)NCc1cccc(CNCc2ccc(Oc3ccc(F)cc3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.52
EPHX2 P34913 2/20 0.52
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
RAB9A P51151 1/20 0.49
HPGD P15428 1/20 0.49
PTGER4 P35408 1/20 0.48
PTGER2 P43116 1/20 0.48
MAPK14 Q16539 3/20 0.48
CYP3A4 P08684 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184800 0.91 LTA4H (0.50) LTA4HEPHX2HTTSMN1; SMN2PTGER4
SCHEMBL15157842 0.88 SRC (0.54) ALDH1A1KDM4EHTTSMN1; SMN2RAB9A
SCHEMBL184462 0.83 GRM2 (0.48) LTA4HEPHX2ALDH1A1KDM4EHTT
SCHEMBL184560 0.83 HTT (0.59) ALDH1A1KDM4EHTTSMN1; SMN2RAB9A
SCHEMBL185065 0.81 CYP1A2 (0.68) ALDH1A1SMN1; SMN2HPGDCYP1A2CYP2D6
SCHEMBL8809055 0.80 KDM4E (0.71) LTA4HEPHX2ALDH1A1KDM4EHTT
SCHEMBL27812213 0.78 SMN1; SMN2 (0.45) LTA4HEPHX2ALDH1A1KDM4EHTT
SCHEMBL1728537 0.78 MAPK14 (0.68) LTA4HEPHX2ALDH1A1HTTSMN1; SMN2
SCHEMBL8497924 0.78 LTA4H (0.79) LTA4HEPHX2ALDH1A1KDM4EHTT
SCHEMBL184150 0.78 LMNA (0.61) ALDH1A1KDM4ESMN1; SMN2CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 LTA4H 3471/4885EPHX2 3168/4885ALDH1A1 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.